Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation

Authors: Stefanie Schmidt, Ricard Riel, Albert Frances, José Antonio Lorente Garin, Xavier Bonfill, María José Martinez-Zapata, Maria Morales Suarez-Varela, Javier dela Cruz, José Ignacio Emparanza, María-José Sánchez, Javier Zamora, Juan Manuel Ramos Goñi, Jordi Alonso, Montse Ferrer

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties.

Methods

For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach’s alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness.

Results

Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53.

Conclusions

The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49: 1374–1403. 10.1016/j.ejca.2012.12.027CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49: 1374–1403. 10.1016/j.ejca.2012.12.027CrossRefPubMed
2.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10–29. 10.3322/caac.20138CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62: 10–29. 10.3322/caac.20138CrossRefPubMed
3.
go back to reference Soreide K, Soreide AH: Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology? Front Oncol 2013, 3: 157.PubMedCentralCrossRefPubMed Soreide K, Soreide AH: Using patient-reported outcome measures for improved decision-making in patients with gastrointestinal cancer - the last clinical frontier in surgical oncology? Front Oncol 2013, 3: 157.PubMedCentralCrossRefPubMed
4.
go back to reference Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD: Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309: 814–822. 10.1001/jama.2013.879CrossRefPubMed Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD: Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013, 309: 814–822. 10.1001/jama.2013.879CrossRefPubMed
5.
go back to reference Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, et al.: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012, 30: 4249–4255. 10.1200/JCO.2012.42.5967CrossRefPubMed Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, et al.: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012, 30: 4249–4255. 10.1200/JCO.2012.42.5967CrossRefPubMed
6.
go back to reference Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A: Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 2003, 12: 675–688. 10.1023/A:1025144617752CrossRefPubMed Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A: Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 2003, 12: 675–688. 10.1023/A:1025144617752CrossRefPubMed
7.
go back to reference Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK: The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC quality of life study group. Qual Life Res 1998, 7: 291–300. 10.1023/A:1008890401133CrossRefPubMed Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK: The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC quality of life study group. Qual Life Res 1998, 7: 291–300. 10.1023/A:1008890401133CrossRefPubMed
8.
go back to reference Cookson MS, Dutta SC, Chang SS, Clark T, Smith JA Jr, Wells N: Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol 2003, 170: 1926–1930. 10.1097/01.ju.0000092830.03247.efCrossRefPubMed Cookson MS, Dutta SC, Chang SS, Clark T, Smith JA Jr, Wells N: Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. J Urol 2003, 170: 1926–1930. 10.1097/01.ju.0000092830.03247.efCrossRefPubMed
9.
go back to reference Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MS, Penson DF: Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology 2012, 80: 77–83. 10.1016/j.urology.2012.01.090CrossRefPubMed Anderson CB, Feurer ID, Large MC, Steinberg GD, Barocas DA, Cookson MS, Penson DF: Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology 2012, 80: 77–83. 10.1016/j.urology.2012.01.090CrossRefPubMed
10.
go back to reference Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT: Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007, 109: 1756–1762. 10.1002/cncr.22556CrossRefPubMed Gilbert SM, Wood DP, Dunn RL, Weizer AZ, Lee CT, Montie JE, Wei JT: Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007, 109: 1756–1762. 10.1002/cncr.22556CrossRefPubMed
11.
go back to reference Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT: Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol 2010, 183: 1764–1769. 10.1016/j.juro.2010.01.013CrossRefPubMed Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT: Development and validation of the Bladder Cancer Index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol 2010, 183: 1764–1769. 10.1016/j.juro.2010.01.013CrossRefPubMed
12.
go back to reference Scientific Advisory Committee of the Medical Outcomes Trust: Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002, 11: 193–205. 10.1023/A:1015291021312CrossRef Scientific Advisory Committee of the Medical Outcomes Trust: Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002, 11: 193–205. 10.1023/A:1015291021312CrossRef
13.
go back to reference Ware JE, Kosinski M, Dewey JE: How to Score. Version 2 of the SF-36 Health Survey (Standard & Acute Forms). Quality Metric Incorporated: Lincoln RI; 2000. Ware JE, Kosinski M, Dewey JE: How to Score. Version 2 of the SF-36 Health Survey (Standard & Acute Forms). Quality Metric Incorporated: Lincoln RI; 2000.
15.
go back to reference Cohen A: Statistical Power for the Behavioral Sciences. Hillsdale, NJ: Lawrence Eribaum; 1988. Cohen A: Statistical Power for the Behavioral Sciences. Hillsdale, NJ: Lawrence Eribaum; 1988.
16.
go back to reference Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 1989, 27: S178-S189. 10.1097/00005650-198903001-00015CrossRefPubMed Kazis LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care 1989, 27: S178-S189. 10.1097/00005650-198903001-00015CrossRefPubMed
17.
go back to reference Holck Storås A, Sanda M, Ferrer M, Loge J, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD: Localized prostate cancer in Norway, USA and Spain: between-country differences of pretreatment variables among patients eligible for curative treatment. J Gynecol Oncol 2014. [ahead of publishing] Holck Storås A, Sanda M, Ferrer M, Loge J, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD: Localized prostate cancer in Norway, USA and Spain: between-country differences of pretreatment variables among patients eligible for curative treatment. J Gynecol Oncol 2014. [ahead of publishing]
18.
go back to reference Gaunez N, Larre S, Pires C, Dore B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol 2010, 22: 350–353.CrossRefPubMed Gaunez N, Larre S, Pires C, Dore B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol 2010, 22: 350–353.CrossRefPubMed
Metadata
Title
Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation
Authors
Stefanie Schmidt
Ricard Riel
Albert Frances
José Antonio Lorente Garin
Xavier Bonfill
María José Martinez-Zapata
Maria Morales Suarez-Varela
Javier dela Cruz
José Ignacio Emparanza
María-José Sánchez
Javier Zamora
Juan Manuel Ramos Goñi
Jordi Alonso
Montse Ferrer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-12-20

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue